We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Beximco Pharma | LSE:BXP | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 40.50 | 39.00 | 42.00 | 41.40 | 40.50 | 40.50 | 30,494 | 08:00:25 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/8/2020 16:17 | Thanks Greg. | davebowler | |
28/8/2020 16:11 | Dhaka open on Sunday so maybe more fuel to the share price for a BIG monday rise. As previously mentioned, UK press coverage also a major factor. GLA | greg the grinch | |
28/8/2020 16:07 | Deal with AZN should hopefully allay 'dodgy' company fears, and ER has been reasonably stable. I do know shares are not fungible so no arbitrage opportunities. Still too much of a discount - hopefully this deal can help. | greg the grinch | |
28/8/2020 15:49 | The price difference is more likely due to the view from the UK of less regulatory and financial oversight of companies in countries like Bangladesh. There is also the issue of exchange rate fluctuations. | cb7 | |
28/8/2020 15:37 | osc.c So BXP cant buy the AIM BXP shares? - hence the price difference? TIA | greg the grinch | |
28/8/2020 14:14 | Bought some today. Rarely buy at highs but know this company from years ago and fair chance of media attention at weekend. Great announcement and having AZ onside is significant. SNG and AVCT multibagged overnight on similar type news, this hasn't and could be delayed action gain | microscope | |
28/8/2020 13:40 | The usual discount difference between the UK ADRs price and the Dhaka shares price is because the Bangladeshi Govt. have mandated that the Company cannot buy back in it's ADRs. And because it's an ADR in the UK, rather than an ordinary share, all share news outlets don't carry it's news, so it's completely under the radar. e,g. look for this today on the "news headlines" page of ADVFN. It's not there. The one HUGE takeaway from today's news is that 2 potential eventual buyers for the Company have been flagged up in AZN and SII. And, of course, any offer in Dhaka translates equally to the UK, so any takeover gives us 30%-40% more upside than Dhaka shareholders. In the meantime, although debt is moderately high, they still pay a good divvy. | outsizeclothes.com | |
28/8/2020 11:59 | I'm off to sit and wait, see you in a while. | greg the grinch | |
28/8/2020 11:58 | Hmm... makes me wonder if the differential is caused by a large holder mistakenly tracking the wrong share? Possibly set to auto-track with the wrong settings? | greg the grinch | |
28/8/2020 11:55 | You need to look at beximco pharma NOT beximco. which was the original parent company. This is the correct one This is NOT the correct one GLA £ to Taka approx 1 : 1.12 | greg the grinch | |
28/8/2020 11:49 | Well summarised PharmaGiles. I’ve been here since the 30s and 40s. I think it is a really key point to note that Dhaka is closed today. All eyes on movement next week. | toadhall1 | |
28/8/2020 11:38 | It's currently 95p equivalent on the Dhaka Stock Exchange (DSE) - but the DSE is closed on Friday's (hence no lift today). The GDRs (on AIM) are = to the ordinary shares on the DSE but to-date we haven't seen parity between the DSE and AIM SPs. They're also selling Remdesivir into 10 countries - through the Bangladesh government, and reportedly were making 160,000 vials this month, with plans to significantly scale up production. They pretty much make all the COVID drugs, and also big in inhalers - which could be relevant as Remdesivir is exploring the inhaler route (as are companies like Synairgen).. Dividends are paid out annually, to those on the books in Nov, and this year the rules are they should pay out 30% of profits to shareholders. Profits are likely to have increased over last years, but potentially growth may not be double digit for the first time for a while, due to a potential/temporary dip in Q4 (April - June) - which looks set to recover in Q1 (July - Sept). The generics market is relatively low risk - as long as you're competing on price (which they can). Been here for a while so nice to see the rise - although I still think undervalued. | pharma giles | |
28/8/2020 11:11 | Yes -I wonder if there has been dilution -its price is 26.2 in Dhaka but 65p in BDT is 73 BDT!! hxxps://www.xe.com/c | davebowler | |
28/8/2020 10:59 | Can anyone explain how the AIM share price and the Dhaka share price relate. Or do they not at all? | fegger | |
28/8/2020 10:46 | Hmmm... interesting to see if this leads to more deals with AZN.... or AZN buy them out? GLA | greg the grinch | |
28/8/2020 10:41 | Here is another Dhaka price graph - different time scale. | greg the grinch | |
28/8/2020 10:39 | I am waiting for the buyout - that way the AIM share price reduction (for some unknown reason always lower than Dhaka) will disappear. I guess £2, if and when it happens. This deal will do a lot for the image of BXP and hopefully help erase the price differential. I think med/long term the price will keep chugging up. GLA | greg the grinch | |
28/8/2020 09:34 | Well done all who held on! | zcaprd7 | |
28/8/2020 09:31 | the wait from April 2017 from which point the share price was on a downward trend has been for the patient. hopefully that patience will now be rewarded. | mfhmfh | |
28/8/2020 09:23 | Great news but dont know anything about this co.Are they well financed. No numbers mentioned today but seems exciting just the same!!! | billthebank | |
28/8/2020 09:07 | Wouldnt be surprised to see this multibag today. Impossible to buy and huge news given the Astrazenca tie in. | genierub |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions